PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
Open Access
- 11 February 2010
- journal article
- Published by H1 Connect in F1000 Biology Reports
- Vol. 2 (10)
Abstract
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancerKeywords
This publication has 11 references indexed in Scilit:
- DNA Damage, Aging, and CancerNew England Journal of Medicine, 2009
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersNature Medicine, 2009
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersNew England Journal of Medicine, 2009
- Synthetic Lethality — A New Direction in Cancer-Drug DevelopmentNew England Journal of Medicine, 2009
- Targeted therapy for cancer using PARP inhibitorsCurrent Opinion in Pharmacology, 2008
- BRCA1 regulates human mammary stem/progenitor cell fateProceedings of the National Academy of Sciences, 2008
- Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancersBreast Cancer Research and Treatment, 2007
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- The relationship between the roles of BRCA genes in DNA repair and cancer predispositionTrends in Molecular Medicine, 2002